NCT00826280View on ClinicalTrials.gov

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

PHASE3CompletedINTERVENTIONAL
Enrollment

347

Participants

Timeline

Start Date

March 24, 2009

Primary Completion Date

July 15, 2010

Study Completion Date

July 15, 2010

Conditions
Coronary Artery Disease (CAD)
Interventions
DRUG

regadenoson

IV

DRUG

overencapsulated caffeine

oral

RADIATION

technetium

IV

DRUG

placebo

oral

Trial Locations (25)

12205

Albany

19102

Philadelphia

19173

Newark

19610

Wyomissing

32216

Jacksonville

33173

Miami

33321

Tamarac

35294

Birmingham

35801

Huntsville

37920

Knoxville

43214

Columbus

48197

Ypsilanti

48202

Detroit

60504

Aurora

64111

Kansas City

66209

Overland Park

91942

La Mesa

92691

Mission Viejo

95405

Santa Rosa

95661

Roseville

95819

Sacramento

06102-5037

Hartford

04210

Auburn

01201

Pittsfield

14642-8679

Rochester

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY